Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001609492-26-000006
Filing Date
2026-05-12
Accepted
2026-05-12 19:56:22
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 24760
2 EXHIBIT 99.C - JOINT FILING STATEMENT ex-99-05122026_110506.htm EX-99.C 13504
  Complete submission text file 0001609492-26-000006.txt   40023
Mailing Address C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116
Business Address C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 (617) 425-9200
MPM BioVentures 2014, L.P. (Filed by) CIK: 0001609492 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Subject) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92515 | Film No.: 26970438
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)